Orchid Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 20, 2025
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Orchid Pharma has submitted its 32nd Annual Report and Notice of AGM to the exchanges, with the AGM scheduled for September 20, 2025 at 11:30 AM via video conferencing. For FY 2024-25, the company reported strong growth with revenue from operations rising to Rs. 921.93 crores from Rs. 819.37 crores in FY24, and EBITDA improving to Rs. 155.46 crores from Rs. 141.07 crores. Profit After Tax grew to Rs. 106.48 crores (versus Rs. 94.75 crores), and EPS stood at Rs. 20.99 compared to Rs. 19.59 previously. Key highlights include the full repatriation of global rights to its novel antibiotic Enmetazobactam (EXBLIFEP/Orblicef) following the acquisition of Allecra Therapeutics' assets, USFDA issuing an EIR with VAI status for its facility, and NCLT approval of the First Motion Application for the merger of Dhanuka Laboratories into Orchid Pharma. The Board has not recommended any dividend, opting to retain profits for expansion projects.
For shareholders, this is largely a procedural AGM notice, but the accompanying Annual Report reveals solid financial improvement with revenue up ~12.5% and PAT up ~12%, alongside strategic moves like the Enmetazobactam acquisition and the Dhanuka merger that could enhance long-term value. The absence of a dividend signals reinvestment into growth, which may appeal to investors focused on capital appreciation rather than near-term income.